Cecilia Beatriz Dobrecky

Dr. Cecilia Beatriz Dobrecky

Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Tecnología Farmacéutica, Buenos Aires 1113, Argentina

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 July 2020 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
PDF file
Cecilia Beatriz DobreckyCecilia Beatriz Dobrecky
Cecilia Beatriz Dobrecky
TMTimoteo Marchini
Timoteo Marchini
RRRafael Ricco
Rafael Ricco
MGMariana Garcés
Mariana Garcés
AGAndrea Gadano
Andrea Gadano
PEPablo A. Evelson
Pablo A. Evelson

28 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
OBOriana Boscolo
Oriana Boscolo
SFSabrina Flor
Sabrina Flor
LSLeandro Salvo
Leandro Salvo
Cecilia Beatriz DobreckyCecilia Beatriz Dobrecky
Cecilia Beatriz Dobrecky
CHChristian Höcht
Christian Höcht
Silvia Edith LucangioliSilvia Edith Lucangioli
Silvia Edith Lucangioli
Background: Ursodeoxycholic acid (UDCA) is a therapeutic agent used for the treatment of cholestatic hepatobiliary diseases in pediatric patients. It is a bile acid that presents high lipophilicity, and it belongs to Class II of the Biopharmaceutical Classification System (BCS), which exhibits low water solubility and high intestinal permeability, which leads to poor oral absorption. The objective of this work was to design and optimize UDCA nanosuspensions by means of the precipitation-ultrasonication method to improve the solubility, dissolution, and oral bioavailability of UDCA. Methods: A three-level, three-factor Box–Behnken design was used to optimize formulation variables and obtain uniform, small-particle-size UDCA nanosuspensions. The independent variables were: stabilizer percentage (X1), amplitude (X2), and sonication time (X3), and the dependent variable was the particle size (Y1). In the precipitation–ultrasonication method, UDCA was dissolved in acetone:PEG 400 (1:1 v/v) and quickly incorporated into the antisolvent (pre-cooled aqueous dispersion of HPMC E-15 0.3%), by means of intense sonication at 50 W for 5 min, controlling temperature through an ice water bath. The lyophilization efficacy was evaluated by means of a cryoprotective efficacy test, working with 10% maltose at −80 °C. The nanosuspensions were characterized by dynamic light scattering (DLS), X-ray diffraction, and scanning electron microscopy (SEM). The physicochemical stability was determined at 25 °C and 4 °C at 7, 14, 30, and 60 days, and the UDCA content was analyzed via HPLC-UV. An in vitro dissolution assay and an oral bioavailability study were performed in male Wistar rats. Results: A significant impact was achieved in the optimized nanosuspension with 0.3% (stabilizer), 50 W (amplitude), and 5 min (sonication time), with a particle size of 352.4 nm, PDI of 0.11, and zeta potential of −4.30 mV. It presented adequate physicochemical stability throughout the study and the UDCA content was between 90% and 110%. In total, 86% of UDCA was dissolved in the in vitro dissolution test. The relative oral bioavailability was similar without significant statistical differences when comparing the lyophilized nanosuspension and the commercial tablet, the latter presenting a more erratic behavior. The pharmacokinetic parameters of the nanosuspension and the commercial tablet were Tmax (1.0 ± 0.9 h vs. 2.0 ± 0.8 h, respectively), Cmax (0.558 ± 0.118 vs. 0.366 ± 0.113 µM, respectively), ΔCmax (0.309 ± 0.099 vs. 0.232 ± 0.056, respectively), AUC (4.326 ± 0.471 vs. 2.188 ± 0.353 µg/mL.h, respectively, p < 0.02), and IAUC0–24h (2.261 ± 0.187 µg/mL.h vs. 1.924 ± 0.440 µg/mL.h, respectively). Conclusions: The developed nanosuspension presents an appropriate dosage and administration for pediatric patients. On the other hand, it exhibits an adequate absorption and UDCA oral bioavailability.

23 September 2022 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
Cecilia Beatriz DobreckyCecilia Beatriz Dobrecky
Cecilia Beatriz Dobrecky
SLSilvia E. Lucangioli
Silvia E. Lucangioli
MWMarcelo L. Wagner
Marcelo L. Wagner

30 September 2024 in Journal of Pharmacopuncture
Verified
Journal Article
Open access
PDF file
EMElina Malén Saint Martin
Elina Malén Saint Martin
ASAyelen Morena Sosa
Ayelen Morena Sosa
CMCarolina Martinez
Carolina Martinez
MPMaria Jimena Prieto
Maria Jimena Prieto
CMCarla Marrassini
Carla Marrassini
CAClaudia Anesini
Claudia Anesini
Elina Malén Saint Martin, Ayelen Morena Sosa, Carolina Soledad Martinez, Jimena Prieto, Carla Marrassini, Cecilia Beatriz Dobrecky, María Rosario Alonso, Claudia Anesini. J Pharmacopuncture 2024;27:211-22. https://doi.org/10.3831/KPI.2024.27.3.211

24 December 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
COCamila Belen Olivera
Camila Belen Olivera
OBOriana Boscolo
Oriana Boscolo
Cecilia Beatriz DobreckyCecilia Beatriz Dobrecky
Cecilia Beatriz Dobrecky
COClaudia Alicia Ortega
Claudia Alicia Ortega
LFLaura Favier
Laura Favier
Silvia Edith LucangioliSilvia Edith Lucangioli
Silvia Edith Lucangioli
Background: Trihexyphenidyl (THP) has been widely used for over three decades as pediatric pharmacotherapy in patients affected by segmental and generalized dystonia. In order to achieve effective and safe pharmacotherapy for this population, new formulations are needed. Objective: The aim of this work is the development of trihexyphenidyl orodispersible minitablets (ODMTs) for pediatric use. Methods: Six different excipients were tested as diluents. The properties of powder mixtures were evaluated before direct compression and pharmacotechnical tests were performed on the final formulation. The determination of the API content, uniformity of dosage, and physicochemical stability studies were analyzed by an HPLC-UV method. Results: The developed ODMTs met pharmacopeia specifications for content, hardness, friability, disintegration, and dissolution tests. The physicochemical stability study performed over 18 months shows that API content remains within 90.0–110.0% at least for this period. Conclusions: These ODMTs will allow efficient, safe, and high-quality pharmacotherapy.

19 September 2022 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
DRDaiana Sabrina Retta
Daiana Sabrina Retta
PLPaola Di Leo Lira
Paola Di Leo Lira
MBMaricel Bálsamo
Maricel Bálsamo
MDMacarena Delpupo
Macarena Delpupo
VMValeria A. Moscatelli
Valeria A. Moscatelli
CBCatalina M. van Baren
Catalina M. van Baren